# US 2009/0221606 A1 · Crystalline (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl) piperazin-1-ylimethanone phosphate

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0221606 A1
- Document ID: US20090221606A1
- Status: Published application
- Kind: A1
- Application number: 12/299,554
- Filed: 2007-04-24
- Published: 2009-09-03
- Earliest claimed: 2006-05-05
- Assignees: Merck Patent GmbH
- Inventors: Susan Marie Reutzel-Eden; Gregory Alan Stephenson
- Web page: https://patentgrep.com/patent/US20090221606A1

## CPC

- C07D 209/42: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/24: Antidepressants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel crystalline forms of (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate and to pharmaceutical compositions containing said forms.

## Claims

### Claim 1

A crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1yl]methanone phosphate hydrate.

### Claim 2

A crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1yl]methanone phosphate hydrate Form I, characterized by a CuKα radiation X-ray powder diffraction pattern comprising peaks at 2θ values of 8.1 and 15.6.

### Claim 3 (depends on 2)

The crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1yl]methanone phosphate hydrate Form I according to claim 2, characterized by a CuKα radiation X-ray powder diffraction pattern comprising peaks at 2θ values of 8.1, 15.6 and 17.4.

### Claim 4 (depends on 2)

The crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate hydrate Form I according to claim 2, characterized by a CuKα radiation X-ray powder diffraction pattern comprising peaks at 2θ values of 8.1, 15.6, 17.4 and 18.5.

### Claim 5 (depends on 2)

The crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate hydrate Form I according to claim 2, characterized by a CuKα radiation X-ray powder diffraction pattern comprising peaks at 2θ values of 8.1, 15.6, 17.4, 18.5 and 21.9.

### Claim 6 (depends on 1)

The crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate hydrate Form I according to claim 1, further characterized by a CuKα radiation X-ray powder diffraction pattern comprising a doublet of peaks at 2θ values of 12.0 and 12.2.

### Claim 7 (depends on 2)

The crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate hydrate Form I according to claim 2, characterized by a solid state 13C nuclear magnetic resonance spectrum comprising chemical shift peaks at 84.0-84.7+/−0.2 and 166.8-167.5+/−0.2 ppm.

### Claim 8 (depends on 2)

The crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1yl]methanone phosphate hydrate Form I according to claim 2, characterized by solid state 13C nuclear magnetic resonance spectrum comprising chemical shift peaks at 84.0-84.7+/−0.2, 166.8-167.5+/−0.2, and 159.8-160.7+/−0.2 ppm.

### Claim 9

A crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1yl]methanone phosphate anhydrate.

### Claim 10 (depends on 9)

The crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1yl]methanone phosphate anhydrate according to claim 9, characterized by a CuKα radiation X-ray powder diffraction pattern comprising peaks at 2θ values of 8.0 and 12.5.

### Claim 11 (depends on 9)

The crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate anhydrate according to claim 9, characterized by a CuKα radiation X-ray powder diffraction pattern comprising peaks at 2θ values of 8.0, 12.5, and 18.3.

### Claim 12 (depends on 9)

The crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate anhydrate according to claim 9, characterized by a CuKα radiation X-ray powder diffraction pattern comprising peaks at 2θ values of 8.0, 12.5, 18.3, and 15.8.

### Claim 13 (depends on 9)

The crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate anhydrate according to claim 9, characterized by a CuKα radiation X-ray powder diffraction pattern comprising peaks at 2θ values of 8.0, 12.5, 18.3, 15.8, and 23.3.

### Claim 14 (depends on 1)

A composition comprising crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate according to claim 1 as an active ingredient in association with a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 15 (depends on 1)

A pharmaceutical composition in unit dosage form comprising between approximately 0.1 and 500 mg of crystalline (3-cyano-1H-indol-7-yl)-[4-(4fluorophenethyl)piperazin-1-yllmethanone phosphate hydrate according to claim 1 as an active ingredient in association with a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 16 (depends on 1)

A pharmaceutical composition in unit dosage form comprising between approximately 5.0 and 300 mg of crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate according to claim 1 as an active ingredient in association with a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 17 (depends on 2)

A composition comprising crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate hydrate Form I according to claim 2 as an active ingredient in association with a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 18 (depends on 9)

A composition comprising crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1yl]methanone phosphate anhydrate according to claim 9 as an active ingredient in association with a pharmaceutically acceptable carrier, diluent or excipient.

### Claim 19 (depends on 10)

A composition comprising crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1yl]methanone phosphate anhydrate according to claim 10 as an active ingredient in association with a pharmaceutically acceptable carrier, diluent or excipient.
